Symposium on

Modern Trends in Radiopharmaceutical Sciences

Institute of Neurosciences and Medicine, INM-5: Nuclear Chemistry
Forschungszentrum Jülich (FZJ), Germany, 05 May 2009
Hörsaal, Gebäude 05.3

Programme

08:45 Uhr	Welcome and opening Prof. Dr. S. Schmidt, Board of Directors, FZJ, Jülich  H.H. Coenen, President SRS, FZJ, Jülich
09:00 Uhr	Can photons meet the challenge of producing Mo-99? T. Ruth, TRIUMF, Vancouver
09:30 Uhr	Nuclear data for the production of non-standard PET-radionuclides. S.M. Qaim, FZJ, Jülich
10:00 Uhr	Preparation and use of high specific activity radiometals. C. Cutler, University of Missouri, Columbia, MO
10:30 Uhr	Coffee break
11:00 Uhr	Recent attempts for the application of Re-188 in cancer radiotherapy. U. Mazzi, University of Padua, Padua
11:30 Uhr	New studies with radiolabled bombesin derivatives for imaging and therapy. W. Volkert, University of Missouri, Columbia, MO
12:00 Uhr	Hypoxic tumour stem cell as a target for PET imaging/radiotherapy. Y. Fujibayashi, University of Fukui, Fukui
12:30 Uhr	Lunch break
14:00 Uhr	B12-derivates – A promising tumour biomarker. P. A. Schubiger, ETH/PSI, Zürich
14:30 Uhr	Multimeric receptor binding and the role of ligand rigidity. M. Eisenhut, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
15:00 Uhr	Radiopharmaceuticals for imaging PgP function with PET; [¹¹C]Verapamil, its radiometabolite [¹¹C]D617 and the new radiopharmaceutical [^11C]Laniquidar. A.D. Windhorst, Free University of Amsterdam, Amsterdam
15:30 Uhr	Coffee break
16:00 Uhr	Changes in latitudes, changes in attitudes. W.C. Eckelman, Molecular Tracer LLC, Bethesda, MD
16:30 Uhr	EU and US regulatory considerations for PET radiopharmaceuticals. S. Schwarz, Washington University, St. Louis, MO
17:00 Uhr	Training program for PET radiopharmaceutical sciences: Addressing a global shortage. S. Mcquarrie, University of Alberta, Edmonton
17:30 Uhr	Round table discussion
18:00 Uhr	Closing, farewell